Tiny birth control stock soars following Roe v. Wade overturn
Sources: Roberts fought to the end to save Roe v. WadeReplayMore Videos ... (16 Videos)Sources: Roberts fought to the end to save Roe v. Wade'Damaging and stigmatizing': NYC Health Commissioner on past discriminatory messaging around virusesCNN reporter shares 5 tips to stay cool in extreme temperaturesTexas woman speaks out after being forced to carry her dead fetus for 2 weeksWhat you need to know about new Omicron offshootHow Alzheimer's disease destroys the brainCan a formula be racist? She says one put her health at risk Video: How mountain bikers stay calm 3,600 feet in the airShe was 7 weeks pregnant. She felt her only option was to order abortion pills onlineSanjay Gupta explains how scientists are trying to 'outsmart cancer'FDA commissioner describes unsanitary conditions at Abbott baby formula plantWhy the baby formula shortage is hitting these moms hardest'Tumors just vanished': Cancer patients now in remission after drug trialCNN reporter makes plea to gun owners after colleague shot and killedShortage of this contrast dye is forcing hospitals to ration CT scansMan who received genetically modified pig heart in transplant surgery diesNew York (CNN Business)There's a saying on Wall Street that traders often sell the news. Well, that hasn't been the case with a tiny reproductive health company following the Supreme Court's decision to overturn Roe v. Wade last month.
Shares of Evofem Biosciences (EVFM), which makes a hormone-free contraceptive vaginal gel named Phexxi, have more than doubled since the court ruled that abortion rights are no longer federally protected by the Constitution, leaving it up to states to decide whether or not to ban abortions.Evofem Biosciences had already been preparing for more interest in its products even before the ruling was official."When women are denied safe, legal abortion, the importance of access to FDA-approved contraception is greater than it has ever been," Saundra Pelletier, president and CEO of Evofem Biosciences, said during the company's latest earnings call in early May, just days after a draft version of the Supreme Court's majority opinion was leaked.The inside story of how John Roberts failed to save abortion rightsStill, the big move in the stock has caught the attention of skeptical traders as well. Short sellers — investors who borrow shares and sell them with the hopes of buying them back at a lower price and pocketing the difference — have ramped up their bets against the stock.Read MoreS&P Global Market Intelligence noted in a report last week that Evofem Biosciences is now one of the most heavily shorted stocks in the entire market. The amount of stock being held short, known as short interest, in the company went up from about 6% of available shares in mid-June to more than 50% by the end of that month. This clearly shows that there are big risks — in addition to the possible rewards — from trying to trade stocks based on headlines. Even though Evofem Biosciences shares are still up sharply from their pre-Dobbs v. Jackson Women's Health Organization ruling levels, the stock has pulled back sharply from its post-decision peak. Evofem Biosciences now trades at around 80 cents a share, after hitting a high of $1.57 in early July. (The stock was below 40 cents before the Supreme Court ruling.) Trading volume has been extremely high as well, a sign of the increased interest from both bulls and bears.Evofem Biosciences isn't the only small reproductive healthcare stock that's been on a wild ride in the past month. Femasys, which is developing what it claims will be a permanent contraceptive solution called FemBloc, is up nearly 40% since Roe v. Wade was overturned.Click Here To Get Funded!